Showing 2,381 - 2,400 results of 3,304 for search '"clinical trials"', query time: 0.10s Refine Results
  1. 2381

    Stratification system with dual human endogenous retroviruses for predicting immunotherapy efficacy in metastatic clear-cell renal cell carcinoma by Li Xu, Stephane Oudard, Catherine Sautes-Fridman, Xiaoping Su, Gabriel G. Malouf, Virginie Verkarre, Salma Kotti, Fangrong Yan, Yann-Alexandre Vano, Wolf Herve Fridman, Cheng-Ming Sun, Xiaofan Lu, Wenxuan Cheng

    Published 2025-01-01
    “…While the dysregulation of ERV transcription has been linked to immune cell infiltration in various cancers, its relationship with immune checkpoint inhibitor (ICI) response in solid tumors, particularly metastatic clear-cell renal cell carcinoma (ccRCC), remains inadequately explored.Methods This study analyzed patients with metastatic ccRCC from two prospective clinical trials, encompassing 181 patients receiving nivolumab in the CheckMate trials (−009 to –010 and −025) and 48 patients treated with the ipilimumab-nivolumab combination in the BIONIKK trial. …”
    Get full text
    Article
  2. 2382
  3. 2383

    Shed antigen-induced blocking effect on CAR-T cells targeting Glypican-3 in Hepatocellular Carcinoma by Wei Gao, Tong Ding, Beicheng Sun, Nan Li, Fang Gao, Meng Jia, Mitchell Ho, Na Li, Luan Sun, Zhanhui Gao, Lei Ao, Sujuan Ma, Peihua Lu, Shaochang Jia

    Published 2021-04-01
    “…Therefore, sGPC3 acted as dominant negative regulators when competed with cell surface GPC3 to bind anti-GPC3 CAR-T cells, leading to an inhibitory effect on CAR-T cells in HCC.Conclusions We provide a proof-of-concept study demonstrating that GPC3 shedding might cause worse response to CAR-T cell treatment by competing with cell surface GPC3 for CAR-T cell binding, which revealed a new mechanism of tumor immune escape in HCC, providing a novel biomarker for patient enrolment in future clinical trials and/or treatments with GPC3-targeted CAR-T cells.…”
    Get full text
    Article
  4. 2384
  5. 2385
  6. 2386
  7. 2387

    Rationale and design of a multicentre randomised controlled trial on circulating tumour DNA-guided neoadjuvant treatment strategy for locally advanced rectal cancer (CINTS-R) by Bin Wu, Yi Xiao, Xiao Zhang, Tao Xu, Qian Liu, Wei Fu, Yang An, Yongheng Li, Guole Lin, Huadan Xue, Guoju Wu, Jiaolin Zhou, Hongwei Yao, Zhenjun Wang, Weijie Chen, Junyang Lu, Guannan Zhang, Xiaoyuan Qiu

    Published 2025-02-01
    “…The results of our trial will be disseminated through peer-reviewed publications and presented at national and international academic conferences.Trial registration number This trial is registered on ClinicalTrials.gov and the registration ID is NCT05601505.…”
    Get full text
    Article
  8. 2388

    Real-world outcomes of the CROSS regimen in patients with resectable esophageal or gastro-esophageal junction adenocarcinoma: a nationwide cohort study in the NetherlandsResearch i... by Hanneke van Laarhoven, Rob Verhoeven, Mark van Berge Henegouwen, Nadia Haj Mohammad, Richard van Hillegersberg, Marije Slingerland, Christina T. Muijs, Bas Wijnhoven, Bianca Mostert, Laurens Beerepoot, Grard Nieuwenhuijzen, Sarah Derks, Peter S.N. van Rossum

    Published 2025-02-01
    “…Interpretation: Although survival rates in real-world settings are often lower compared to clinical trials, in our real-world cohort the 3-year OS was only 2.6% lower compared to that reported for the group that underwent nCRT in ESOPEC. …”
    Get full text
    Article
  9. 2389
  10. 2390
  11. 2391
  12. 2392
  13. 2393
  14. 2394
  15. 2395
  16. 2396
  17. 2397

    Effectiveness–implementation hybrid-2 randomised trial of a collaborative Shared Care Model for Detecting Neurodevelopmental Impairments after Critical Illness in Young Children (D... by Paula Lister, Kristen Gibbons, Zephanie Tyack, Luregn J Schlapbach, Samudragupta Bora, Maria Isabel Castillo, James Best, Debbie Long, Helen G Liley, Belinda Dow, Kerri-Lyn Webb, Christian Stocker, Debra Thoms, Carolyn Wharton, Lori Matuschka

    Published 2022-07-01
    “…Dissemination of the outcomes of the study is expected via publication in a peer-reviewed journal, presentation at relevant conferences, and via social media, podcast presentations and open-access medical education resources.Registration details The trial was prospectively registered with the Australian New Zealand Clinical Trials Registry as ‘Pilot testing of a collaborative Shared Care Model for Detecting Neurodevelopmental Impairments after Critical Illness in Young Children’ (the DAISY Pilot Study).Trial registration number ACTRN12621000799853.…”
    Get full text
    Article
  18. 2398
  19. 2399
  20. 2400